EGF Knockout HEK293 Cell Line

EGF Knockout HEK293 Cell Line
Cat.No.:

EDC08274

Species:

Human

Cell Name:

HEK293

Gene:

EGF

Gene ID:

1950

Size:

1×10⁶cells

EGF Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
Cat.No. EDC08274
Product Name EGF Knockout Cell Line (HEK 293)
Cell Line HEK293
Cellosaurus ID CVCL_0045
Cell Line Synonyms Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293
Gene EGF
NCBI Gene ID
Gene Synonyms HOMG4|URG
Summary
This gene encodes a member of the epidermal growth factor superfamily. The encoded preproprotein is proteolytically processed to generate the 53-amino acid epidermal growth factor peptide. This protein acts a potent mitogenic factor that plays an important role in the growth, proliferation and differentiation of numerous cell types. This protein acts by binding with high affinity to the cell surface receptor, epidermal growth factor receptor. Defects in this gene are the cause of hypomagnesemia type 4. Dysregulation of this gene has been associated with the growth and progression of certain cancers. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. [provided by RefSeq, Jan 2016]
Associated Diseases Non-tumor
Morphology Adherent
Passage Ratio 1/5,2days
Complete Culture Medium DMEM + 10% FBS
Freezing Medium 95% Complete culture medium+ 5% DMSO
QC Indels validated by Sanger sequencing; sterility confirmed via microbial testing.
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
LociSTR Info (Sample Cell)
Sample Cell Line: HEK293
STR Info (Cell bank)
Cell Line: HEK293
Allele1Allele2Allele1Allele2
Amelogenin X X
CSF1P0 12 11 12
D2S1338 19 19
D3S1358 15 17 15 17
D5S818 8 8 9
D7S820 11 12 11 12
D8S1179 12 14 12 14
D13S317 12 14 12 14
D16S539 9 13 9 13
D18S51 17 18 17 18
D19S433 15 18 15 18
D21S11 28 30.2 28 30.2
FGA 23 23
Penta D 9 10 9 10
Penta E 7 15 7 15
TH01 7 9.3 7 9.3
TPOX 11 11
vWA 16 19 16 19
D6S1043 11 11
D12S391 19 21 11 15
D2S441 11 15 11 15
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.

FAQ

The choice depends on whether you are studying EGF (epidermal growth factor)'s role as the prototypical EGFR ligand or its functions in autocrine/paracrine signaling. The Knockout line is the standard tool for asking whether EGF is required for autocrine EGFR signaling — EGF is a 53-amino-acid secreted growth factor (processed from the larger pre-pro-EGF precursor) that binds EGFR (ERBB1) with high affinity, triggering receptor dimerization, autophosphorylation, and downstream PI3K-AKT and RAS-MAPK signaling. Overexpression is useful for studying EGF gain-of-function effects. For EGF-EGFR pathway research, the EDITGENE EGF Knockout in HEK293 enables study of autocrine EGF production. Rescue with wild-type or receptor-binding-deficient EGF enables structure-function studies. The knockout is valuable for studying autocrine EGF signaling, EGFR-targeted cancer therapeutic specificity (cetuximab, panitumumab anti-EGFR antibodies; gefitinib, erlotinib, osimertinib EGFR-TKIs), and emerging EGF-modulating therapeutic strategies.
Primary applications: • EGF secretion: secreted EGF quantification by ELISA in conditioned media to characterize autocrine EGF production. • Autocrine EGFR signaling: phospho-EGFR (Y1068, Y1173), phospho-ERK analysis in EGF-null cells. • Anti-EGFR therapy specificity: complementary specificity control for cetuximab (Erbitux), panitumumab (Vectibix) anti-EGFR antibody specificity testing. • EGFR-TKI mechanism: gefitinib, erlotinib, osimertinib mechanism studies with reduced autocrine EGF. EDITGENE recommends this model for researchers investigating EGF biology, autocrine EGFR signaling, and EGF-EGFR pathway therapeutic development.
Yes. EGF rescue experiments require attention to secreted growth factor processing: • Construct design: EGF is processed from a large pre-pro-EGF precursor (1207 aa) into the mature 53-aa secreted polypeptide — use untagged EGF and quantify secreted form by ELISA, or use precursor with internal tag carefully placed away from the EGF domain. • Secretion validation: confirm conditioned media EGF levels by ELISA before functional assays. • Receptor-binding-deficient rescue: EGFR-binding residue mutations in the mature EGF abolish EGFR activation. • Functional readout: rescue should restore conditioned-media EGF levels and autocrine EGFR activation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.

Required Accessories

Related Products

Flash CRISPR Knockout Kit(Universal Version)Flash CRISPR Knockout Kit(Universal Version)
Flash-Pro CRISPR KO Kit (For Organoids / Stem Cells)Flash-Pro CRISPR KO Kit (For Organoids / Stem Cells)

Related Services

Knockout Cell LineKnockout Cell Line
Contact Us
*
*
*
*
How did you hear about us: